I for one won't be getting over that idea said with all due respect. With a venture capitalist background in a CEO, talks should have been going on well ahead of the FDA approval as to how things would pan out after approval, which we now have. Post approval should have simply been conforming the final numbers and signing a deal (which I still believe is the case here) and informing shareholders.
If they're going at it alone, that's all good and fine, but this should have been told to us days ago. This silence had better be the final deal being worked out because we can't be left in the dark.
Again, I'm only stating how I feel about the situation so I'm sharing my view. But I'd be highly disappointed and would demand management change come March 3rd if I hear "oh we couldn't get a deal done and we're going at it alone". Either way, I'm holding my now doubled down position til at least Mondays call.
News 
Market Data 
Discover 
